

# Salah-Eddine Bentebibel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2310094/publications.pdf>

Version: 2024-02-01

8  
papers

648  
citations

1307594

7  
h-index

1588992

8  
g-index

8  
all docs

8  
docs citations

8  
times ranked

798  
citing authors

#	ARTICLE	IF	CITATIONS
1	LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	14
2	Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. <i>Cancer Cell</i> , 2022, 40, 509-523.e6.	16.8	115
3	Tilgotolimod with Ipilimumab Drives Tumor Responses in Anti-“PD-1 Refractory Melanoma. <i>Cancer Discovery</i> , 2021, 11, 1996-2013.	9.4	32
4	Cytokines in the Treatment of Melanoma. <i>Current Oncology Reports</i> , 2021, 23, 83.	4.0	17
5	Immune Profiling Mass Cytometry Assay Harmonization: Multicenter Experience from CIMAC-CIDC. <i>Clinical Cancer Research</i> , 2021, 27, 5062-5071.	7.0	8
6	Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. <i>Nature Communications</i> , 2020, 11, 661.	12.8	124
7	Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02). <i>Cancer Discovery</i> , 2020, 10, 1158-1173.	9.4	158
8	A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel IL2R $\beta$ -Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors. <i>Cancer Discovery</i> , 2019, 9, 711-721.	9.4	180